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Abstract
Levetiracetam is an FDA-approved drug used to treat epilepsy and other disorders of the nervous system. Although it is
known that levetiracetam binds the synaptic vesicle protein SV2A, how drug binding affects synaptic functioning remains
unknown. Here we report that levetiracetam reverses the effects of excess SV2A in autaptic hippocampal neurons.
Expression of an SV2A-EGFP fusion protein produced a ,1.5-fold increase in synaptic levels of SV2, and resulted in reduced
synaptic release probability. The overexpression phenotype parallels that seen in neurons from SV2 knockout mice, which
experience severe seizures. Overexpression of SV2A also increased synaptic levels of the calcium-sensor protein
synaptotagmin, an SV2-binding protein whose stability and trafficking are regulated by SV2. Treatment with levetiracetam
rescued normal neurotransmission and restored normal levels of SV2 and synaptotagmin at the synapse. These results
indicate that changes in SV2 expression in either direction impact neurotransmission, and suggest that levetiracetam may
modulate SV2 protein interactions.
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Introduction
Levetiracetam ((S)-a-ethyl-2-oxo-pyrrolidine acetamide) repre-
sents a new class of drug for the treatment of neurological and
psychiatric disorders. Currently marketed as KeppraH, levetirace-
tam is FDA-approved for the treatment of epilepsy (reviewed in
[1]), though it also shows promise in the treatment of anxiety
disorders [2,3,4], pain [5,6,7], dyskinesias [8,9,10,11,12], and
post-traumatic stress disorder [3]. The protein receptor for
levetiracetam is Synaptic Vesicle Protein 2A (SV2A) [13], a
membrane glycoprotein specific to the secretory vesicles of
neurons and endocrine cells in vertebrates [14]. SV2A is both
necessary and sufficient for levetiracetam binding [13]. In
addition, mice heterozygous for the SV2A gene disruption show
reduced response to drug treatment [15], consistent with SV2A
being required for levetiracetam action. Thus levetiracetam
appears to act by modulating the action of SV2A, though its
mechanism of action remains unknown.
Mammals have three SV2 genes that encode the isoforms
SV2A, SV2B, and SV2C [16,17,18,19]. Of these, SV2A is the
most broadly expressed, and is present in essentially all neurons
[20]. Notably, it is the only isoform expressed in many inhibitory,
GABAergic neurons [20,21]. SV2A is essential for survival in
mice; gene disruption results in severe seizures and premature
death [22,23]. At the level of the synapse, SV2 acts as a positive
modulator of calcium-dependent exocytosis. Neurons lacking
SV2A or SV2A+B display reduced evoked transmitter secretion
in excitatory [24,25] and inhibitory [22,26] neurons, as well as in
cultured chromaffin cells [27]. In most systems this effect correlates
with a reduction in the number of vesicles able to respond to
increased presynaptic calcium (the readily releasable pool)
[24,25,27]. Thus SV2 appears to act as a positive modulator of
secretory vesicle priming in neuroendocrine cells.
Although its structural similarity to the Major Facilitator
transporter family suggests that SV2 is a transporter, its
demonstrated actions include regulating the expression and
trafficking of the calcium binding protein synaptotagmin [28],
and affecting presynaptic calcium concentrations [25]. This
suggests SV2 may regulate neurotransmission indirectly by
controlling the vesicle’s ability to detect changes in presynaptic
calcium.
Several studies report a correlation between increased SV2
expression and changes in synaptic functioning. Kindling of
seizures in rats results in increased expression of several synaptic
vesicle proteins including SV2 [29,30,31], and SV2A is at the hub
of seizure-dependent changes in protein co-expression [32]. In
addition, mRNA encoding SV2A is a primary target of a
microRNA whose expression is sensitive to changes in synaptic
activity [33]. Together these findings indicate that altered
expression of SV2, and particularly SV2A, is a molecular signature
of altered synaptic activity.
In animals subjected to seizure kindling protocols, treatment
with levetiracetam blocks both the development of a seizure
phenotype and increases in SV2 expression [31,34]. In hippo-
campal slices from non-epileptic animals, treatment with levetir-
acetam reduces neurotransmission in response to fast stimulus
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vesicle priming. Most interestingly, the latency of drug action is
much shorter when neurons are stimulated [36], suggesting that
levetiracetam preferentially targets hyperactive synapses.
Here we report the effects of overexpressing SV2A in
hippocampal neurons cultured to form autaptic synapses. We
found that elevated expression of SV2 resulted in a neurotrans-
mission phenotype that resembled that seen in neurons from SV2
knockout mice, suggesting that too much SV2 is as detrimental to
neuronal function as too little. Because the same neurotransmis-
sion phenotype is associated with seizures in SV2A knockout mice,
this offered the opportunity to assess the effects of levetiracetam
under cellular conditions associated with epilepsy.
Results
Expression of SV2A-EGFP in wild-type neurons reduces
neurotransmitter release
We examined the effect of expressing SV2A-EGFP (SV2A with
enhanced green fluorescent protein (EGFP) fused to the carboxy
terminus) in wild-type autaptic cultures of hippocampal neurons as
part of a larger study designed to assess the effects of mutations in
SV2 [37]. SV2A-EGFP functions like native SV2, as evidenced by
the fact that it restores normal neurotransmission to hippocampal
neurons cultured from SV2A/B knockout mice [28,37]. SV2A-
EGFP trafficked to presynaptic terminals in wild-type neurons,
where it co-localized with the synaptic vesicle protein synapto-
tagmin and synaptophysin (Figure 1).
To our surprise, expression of SV2-EGFP in wild-type
hippocampal neurons resulted in a neurotransmission phenotype
that looked similar to that seen in neurons cultured from SV2A/B
knockout mice. As in neurons from SV2A/B knockout mice,
action potential-induced excitatory postsynaptic currents (EPSC)
were reduced in neurons expressing SV2A-EGFP. EPSC ampli-
tudes were, on average, 65% the amplitude of control neurons
expressing just EGFP (Figure 2). More importantly, the hallmark
feature of the SV2 knockout phenotype, reduced synaptic
depression, was also present in wild-type neurons expressing the
SV2A-EGFP construct. Synaptic depression is a form of short-
term plasticity that correlates with synaptic release probability [38]
and is thus used to measure the ability of synapses to respond to an
action potential. In neurons expressing SV2A-EGFP, responses to
a 10 Hz stimulus train did not decline to the same extent as in
neurons expressing EGFP. This indicates that synaptic release
probability is lower when neurons express elevated levels SV2A.
Levetiracetam restores synaptic depression in wild-type
neurons expressing SV2A-EGFP
Levetiracetam is reported to have multiple subtle effects on
neurons, and the effective concentrations and incubation times for
these different effects vary (reviewed in [39]. The ability of
levetiracetam to reduce neurotransmission in quiescent neurons
requires higher concentrations of drug (100 mM) and relatively
long incubation times ($3 hrs) [35,40]. Thus to determine if
levetiracetam altered the neurotransmission effects of SV2A
overexpression, we examined synaptic depression, the most robust
measure of the overexpression phenotype, in neurons treated with
32 uM or 100 mM levetiracetam for 1 hr or 6–10 hrs. Incubation
with 100 mM levetiracetam for 6–10 hr restored normal synaptic
depression in neurons expressing SV2A-EGFP (Fig. 3B). Treat-
ment for 6–10 hrs with 32 mM also restored synaptic depression,
though the synaptic depression was not of the same magnitude as
with the higher dose (Fig. 3A). A 1 hr treatment did not restore
normal synaptic depression (not shown). These results show that
levetiracetam reverses the synaptic deficit produced by SV2 over-
Figure 1. SV2A-EGFP is trafficked to presynaptic terminals. Neurons expressing either EGFP or an SV2A-EGFP fusion protein were fixed and
processed for immunolabeling. In neurons expressing EGFP green fluorescence was present throughout the length of neurites, whereas in neurons
expressing SV2A-EGFP green fluorescence was punctate. Immunolabeling with anti-SV2 and anti-synaptotagmin revealed that the two proteins co-
localized. Immunolabeling with anti-synaptotagmin and anti-synaptophysin revealed that synaptotagmin co-localized with synaptophysin. The co-
localization of these three presynaptic proteins with SV2A-EGFP indicates that the exogenous fusion protein is trafficked to presynaptic terminals.
doi:10.1371/journal.pone.0029560.g001
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levetiracetam and incubation times previously shown to be
necessary for drug effects on synaptic transmission [35].
As a control, we tested the effects of piracetam, a related
compound with poor anti-seizure action [41] and much lower
affinity for SV2A [42]. Treatment with 32 uM piracetam for 6–
10 hrs did not restore synaptic depression (Fig. 3C). Treatment
with 100 uM piracetam for 6–10 hrs resulted in some synaptic
depression (Fig. 3D), though less than half that seen with
levetiracetam. This is consistent with the effect occurring via
SV2A, which has a higher affinity for levetiracetam than
piracetam.
In contrast to the studies performed in hippocampal slice
preparations [35], levetiracetam did not affect neurotransmission
in uninfected wild type neurons (Fig. 4A) nor did it restore normal
EPSC amplitude or synaptic depression to neurons lacking SV2
(Fig. 4B). Thus overexpression of SV2A is required for
levetiracetam action in this preparation.
Levetiracetam reverses elevated SV2 at synapses
expressing SV2A-EGFP
To determine the extent to which exogenous expression of
SV2A-EGFP and treatment with levetiracetam affected the
amount of SV2 at synapses, we measured synaptic SV2 using
immunolabeling. Hippocampal neurons expressing either EGFP
or SV2A-EGFP were treated with vehicle (water) or 100 mM
levetiracetam for 6 hours, after which they were fixed, permea-
bilized and reacted with an anti-SV2 monoclonal antibody [14]
that recognizes all three isoforms of SV2. Images were collected on
a Deltavision deconvoluting microscope using identical exposure
times and analyzed as described under Methods. Both the total SV2
immunoreactivity per length of neurite and average immunore-
activity intensity at synaptic puncta were quantified. We found
that expression of SV2A-EGFP produced a 1.5-fold increase in the
average intensity (total puncta intensity/puncta area) of SV2
fluorescent puncta, which indicates that there was more SV2 per
synapse in neurons expressing exogenous SV2 than neurons
infected with EGFP lentivirus alone. Incubation with levetirace-
tam reduced this to control levels (Figs. 5A, B). Interestingly,
while expression of SV2A-EGFP led to a ,2-fold increase in the
total amount of SV2 per unit length of neurite, this increase was
not affected by treatment with levetiracetam (Fig. 5C). Together
these findings suggest that levetiracetam influences the localization
of SV2 at the synapse rather than its overall expression or
turnover.
Loss of SV2 results in a significant decrease in the expression
levels of synaptotagmin [28,43,44], suggesting that synaptotagmin
expression/stability depends on SV2. To determine whether
overexpression of SV2 impacts synaptotagmin expression, we
assessed the effect of SV2A-EGFP expression on synaptotagmin
levels. In cells expressing SV2A-EGFP we observed a ,2-fold
increase in the average intensity of anti-synaptotagmin labeled
puncta and a ,3-fold increase in the total amount of
synaptotagmin (immunoreactivity per unit length of neurite)
(Figure 5D–E). Both measures returned to levels seen in control
neurons when cultures were incubated with 100 mM levetiracetam
for 6 hours. Thus levetiracetam restored both total and synaptic
levels of synaptotagmin.
Expression of SV2A-EGFP also increased the density of puncta
labeled with anti-synaptotagmin, suggesting that elevated SV2
levels may lead to more synapses. This increase was not affected by
treatment with levetiracetam, however (Fig. 5F), so it is not clear
that an increase in the number of puncta represents an increase in
functional synapses.
We also assessed the overlap of SV2 and synaptotagmin at the
synapse to determine if either overexpression and/or treatment
with levetiracetam affected protein co-localization at the synapse.
Cultures were co-labeled with anti-SV2 and anti-synaptotagmin
and the fluorescent intensity of SV2 to synaptotagmin was
expressed as a ratio for each punctum. Expression of SV2A-
EGFP resulted in a small but significant decrease in the co-
localization of the two proteins, and this decrease was not affected
by treatment with levetiracetam (Figure 5G).
In summary, we find that levetiracetam treatment of neurons
overexpressing SV2A 1) decreased the amount of both SV2 and
synaptotagmin at synapses (Figures 4B and 4D), 2) decreased total
synaptotagmin/length of neurite but did not restore lower levels of
total SV2 (Figures 4C and 4E), and 3) did not alter the ratio of
Figure 2. Overexpression of SV2A-EGFP in wild-type neurons
results in reduced EPSC amplitude and decreased synaptic
depression. A) Representative traces, average EPSC amplitude, and
average EPSC charge transfer for cultured wild-type (WT) neurons
expressing EGFP or SV2A-EGFP. B) (top) Representative traces of EPSCs
induced by a 10 Hz, 2.5 sec stimulus in WT cells expressing EGFP or
SV2A-EGFP. (bottom) Plot of averaged, normalized EPSC amplitudes in
response to a 10 Hz stimulus train. Data are means 6 SEMs. The
numbers of cells recorded from is indicated in parentheses and is
representative of at least 10 independent cultures. Asterisks indicate a
significant difference in measurement when compared to control
(student’s t-test; *p,0.05).
doi:10.1371/journal.pone.0029560.g002
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consistent with the interpretation that the amount of synaptotag-
min at synapses tracks the amount of SV2, and levetiracetam
results in a reduction in the amount of both proteins available to
support calcium-triggered exocytosis. The fact that both increased
and decreased levels of SV2 and synaptotagmin are associated
with reduced release probability suggests that optimal levels of
these proteins are required for normal neurotransmission, a
conclusion consistent with the recent observation that the number
of SV2s and synaptotagmins per vesicle is tightly regulated [45].
Discussion
The results presented here demonstrate that overexpression of
SV2A produces abnormal neurotransmission that can be rescued
by treatment with levetiracetam. Because expression of SV2A-
EGFP rescues normal neurotransmission in neurons cultured from
SV2A/B knockout mice [28,37], the effects of overexpression are
not likely to be a dominant negative effect of expressing a fusion
protein. Rather they appear to be due to effects of excess SV2. We
note that like SV2, overexpression of the SNARE-binding protein,
complexin, also produces a decrease in synaptic release probability
that resembles that seen in complexin knockout mice
[46,47,48,49,50]. Thus, synaptic functioning can be regulated by
both increases and decreases in protein expression, which suggests
that proteins at the synapse form complexes that rely on precise
stoichiometry in expression levels.
The reduced synaptic release probability we measured in
neurons overexpressing SV2 is nearly identical to that seen in
neurons from SV2A/B knockout mice, which experience severe
seizures [22,23]. Viewed in combination with the results presented
here, it appears that changes in SV2 expression in either direction
have a similar impact on synaptic functioning. Indeed, both
increases and decreases in SV2 expression have been reported to
be associated with the presence of seizues. SV2 expression
increases with kindling of seizures, and both the appearance of
seizures and elevated SV2 expression are reversed by treatment
with levetiracetam [29,31]. In contrast, qualitative analyses of
expression reveal decreased SV2A expression in temporal lobe
epilepsy [51]. Therefore both increased and decreased SV2 may
contribute to epilepsy.
A 6–10 hr treatment with levetiracetam reversed the effects of
SV2 overexpression. The requirement for longer treatment times
was first reported by Yang et al., who showed that levetiracetam-
mediated reduction in synaptic transmission required prolonged
presence of the drug [35,40]. Together with the observation that
Figure 3. Addition of levetiracetam reverses the effect of SV2A overexpression in wild-type neurons. Responses to a 2.5 sec, 10 Hz
stimulus train recorded from WT neurons expressing EGFP or SV2A-EGFP that were incubated for 6–10 hrs in (A)3 2mM leviteracetam, (B) 100 mM
leviteracetam, (C)3 2mM piracetam, or (D) 100 mM piracetam. Neurons incubated in 32 mM or 100 mM leviteracetam displayed normal WT-like
synaptic depression. For each neuron, responses were normalized to the first response in the stimulus train. Graphs show mean 6 SEM. The numbers
of cells recorded from are indicated in parentheses and are representative of 10(A), 6(B), 5(C), and 4(D) independent cultures.
doi:10.1371/journal.pone.0029560.g003
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[27], the delayed action of levetiracetam suggests that it (and
therefore SV2) influences vesicle priming prior to the penultimate
stages of vesicle fusion. Therefore, drug effects will occur after
previously primed vesicles are expended. Consistent with this
interpretation, synaptic activity decreases the latency of levetir-
acetam effects in hippocampal slices [36].
Levetiracetam had no effect on neurons that lacked SV2,
consistent with the conclusion that the drug acts by binding SV2.
Because SV2 expression is limited to presynaptic terminals, this
means that levetiracetam affects presynaptic events that regulate
synaptic vesicle release.
Given that levetiracetam restored the concentration of SV2 at
the synapse (average labeling intensity per synapse area) to control
levels without affecting total SV2 per length of neurite, it is most
likely that levetiracetam affects the ability of SV2 to concentrate in
synapses. This is most consistent with the drug altering SV2’s
ability to bind to proteins that influence protein trafficking or
localization, for example binding to clathrin adaptor proteins or
proteins of the cytoskeleton.
The effects of levetiracetam reported here, in combination
with the observation that levetiracetam blocks kindling-induced
increases in SV2 [34], suggest that levetiracetam may act by
reversing the effects of increased SV2 expression. Because SV2
is part of a protein complex [52], one possible mechanism of
drug action is that it inhibits SV2 protein interactions. In the
case of SV2 overexpression, levetiracetam may inhibit inappro-
priate interactions that occur when SV2 is over-abundant. What
is clear is that levetiracetam’s action on protein levels at
synapses represents a novel drug action. Future work into the
mechanisms by which levetiracetam produces the effects
reported here will provide insight into the etiology of nervous




The generation of SV2A and SV2B knockout mice was reported
previously [22,44]. These animals were used to obtain two lines of
breeders that were SV2A+/2B+/+ or SV2A+/2B2/2. Litter-
mate SV2A+/+B+/+ and SV2A2/2B+/+ mice were obtained by
breeding SV2A+/2B+/+ animals. Similarly, SV2A+/+B2/2 and
SV2A2/2B2/2 littermates were obtained by breeding SV2A+/
2B2/2 animals. All animals were 99.99% C57BL/6. Cultures
weregeneratedfrommiceatpostnatalday0–2.SV2Agenotypewas
determined by PCR before culturing neurons.
The University of Washington IACUC, protocol number 2881-
01, approved the use of mice for these studies.
Figure 4. Levetiracetam has no effect on wild type neurons and does not reverse the SV2A/B knockout neurotransmission
phenotype. Normalized averaged EPSC amplitude, normalized averaged EPSC charge transfer, and plot of normalized responses to a 2.5 sec, 10 Hz
train recorded from neurons cultured (A)W To r( B) SV2A/B double knock-out mice (DKO). Neurons were incubated for 6–10 hrs with vehicle (water) or
100 mM levetiracetam. Shown are mean values 6 SEMs. The numbers of cells recorded from are indicated in parentheses and are representative of
4(A), and 7(B) sets of cultures. Drug treatment had no significant effect on any measure.
doi:10.1371/journal.pone.0029560.g004
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Lentiviral constructs were designed to encode rat SV2A protein
with enhanced-GFP (EGFP) on the carboxy terminus. The
resulting fusion protein serves as a real time visual reporter of
infection and proper protein trafficking. A control vector was
generated encoding EGFP alone. The SV2A-EGFP or EGFP
cDNA was then subcloned into the Lentiviral transfer vector
pRRL-cPPT-CMV-X-PRE-SIN [53]. Lentiviral helper plasmids
(pLP1, pLP2, pLP/VSVG) were from the Virapower packaging
mix (Invitrogen).
Cell culture
Primary cultures of hippocampal neurons were prepared as
previously described [24]. Hippocampi were isolated and the
dentate gyrus was removed. The hippocampi were then incubated
in papain, mechanically dissociated, and plated at a density of
2000–3000 cells/cm2 on coverslips containing microislands of
astrocytes. Astrocyte cultures were derived from wild-type mice.
Levetiracetam or piracetam (Sigma Chemical Company) were
dissolved in sterile water and added to cultures as a 5006 stock
solution. Cultures were infected with Lenti virions 1–3 days after
plating.
Electrophysiology
Whole-cell voltage-clamp recordings were obtained from
neurons on single-neuron islands as previously reported [24]
except that recordings were performed at 21–23uC. Recordings
were performed 10–17 d after plating. For EPSC amplitude
measurements, three responses were obtained and averaged for
each cell.
Data analysis and statistics
Action potential-evoked EPSCs were analyzed with custom
software written in Visual C# (Microsoft, Redmond, WA) as
previously described [24]. EPSC amplitudes were determined by
subtracting a baseline current (obtained by averaging the period
3 ms before the stimulus) from the peak current of the EPSC.
Figure 5. Effects of SV2-EGFP expression and levetiracetam
treatment on synaptic levels of SV2 and synaptotagmin. A)
Neuronal processes labeled with an antibody against SV2 (all isoforms)
revealed punctuate immunofluorescence along the lengths of the
processes. Labeling was more intense in cells expressing SV2A-EGFP
(SV2A) than in wild-type cultures infected with EGFP (EGFP-control). B)
Expression of SV2A-EGFP increases the amount of SV2 at synapses and
treatment with levetiracetam restores normal intensity levels. Shown is
a graph of the average intensity of SV2 immunolabeling in individual
puncta presumed to be synapses. Incubation with 100 mM levetirace-
tam (Lev) for 6–8 hours restored control levels of SV2. C) Expression of
SV2A-EGFP increases the amount of total SV2 in neurites, and treatment
with levetiracetam does not reverse the increase. Shown is a graph of
the fluorescent immunolabeling of SV2 measured as the total intensity
of fluorescence over the total length of neuronal processes in each
image. Incubation with 100 mM levetiracetam (Lev) for 6–8 hours did
not appear to affect on the amount of total SV2 expressed in the
neuronal processes. D) Overexpression of SV2A increases the amount of
synaptotagmin at synapses and treatment with levetiracetam restores
normal intensity levels. Shown is a graph of the average intensity of
synaptotagmin immunolabeling in individual puncta. Incubation with
100 mM levetiracetam (Lev) for 6–8 hours restored control levels of
synaptotagmin. E) Overexpression of SV2A increases the total amount
of synaptotagmin in neurites and treatment with levetiracetam restores
normal levels. Shown is a graph of the fluorescent immunolabeling of
synaptotagmin measured as in C. Incubation with 100 mM levetiracetam
(Lev) for 6–8 hours restored normal synaptotagmin levels. F) Graph of
the number of fluorescent puncta measured per length of neurite in
neurons labeled with anti-synaptotagmin. G) Levetiracetam does not
affect the co-localization of SV2 and synaptotagmin. Shown are graphs
of the fluorescent intensity ratios of SV2 to synaptotagmin in synapses
of the indicated cultures. Protein levels were measured using
fluorescent immunolabeling. Bars represent the mean 6 SEM. Numbers
inside the bars indicate the number of images analyzed and are the
same for B and C, and D and E. Data for B–E are from 4 separate
cultures/replicates and for G from two cultures/replicates. To control for
differences in antibody labeling between repetitions of the study, the
intensity of each synaptic punctum was normalized to the average of all
control (EGFP-infected) puncta within the same replicate. Asterisks
indicate a significant difference in measurement when compared to
EGFP-expressing neurons incubated with vehicle (one-way ANOVA
followed by Fisher’s LSD test; **p,0.01).
doi:10.1371/journal.pone.0029560.g005
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were performed with Microsoft Excel. Reported data are mean 6
SEM. In all cases, t-tests were two-tailed unpaired tests assuming
unequal variances. Immunocytochemistry studies were analyzed
using one-way ANOVA followed by Fisher’s LSD test.
Indirect Immunocytochemistry
For determining the subcellular localization of SV2, cultured
neurons were fixed with 4% paraformaldehyde (EM sciences) in
phosphate buffered saline (PBS) for 20 min at room temperature.
Cells were then washed with PBS containing glycine (0.1 M). PBS
supplemented with 2% normal goat serum, 0.1% bovine serum
albumin, and 0.4% saponin was used for 10 min to block
nonspecific binding and permeabilize cells. The cells were then
incubated with primary antibody against SV2 [14] or synapto-
tagmin [52] overnight at 4uC. Following washout of primary
antibodies, cells were incubated with Alexa-Fluor 568 or Alexa-
Fluor 657-conjugated secondary antibodies (Invitrogen, 1:2000)
for 1 h. Parallel control experiments were performed in which
primary antibodies were omitted to test for the nonspecific binding
of secondary antibodies. Neurons were imaged at the W. M. Keck
Center for Advanced Studies in Neural Signaling using a
DeltaVision microscope (Applied Precision, Issaquah, WA) with
a6 0 6 oil immersion objective, Sedat quad filter set (Chroma
Technologies), Photometrics CH350 CCD camera using Softworx
2.50. A z-series of images was collected at a resolution of
0.113 mm/pixel and deconvolved. A representative z-plane was
chosen for analysis. Images were processed using MetaMorph
(Molecular Devices, Sunnyvale, CA) to measure dendritic length
and to detect and count fluorescent puncta larger than four pixels.
Colocalization of SV2A and synaptotagmin labeling was measured
using MetaMorph. To assess co-localization The percentage of
synaptotagmin-positive cell area that was also positive for
synaptophysin was assessed. All imaging data were background
subtracted using fluorescence emission from a region of the
coverslip containing no cells.
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